INTRODUCTION: Ischemic and pharmacologic preconditioning have great clinical potential, but it remains unclear whether their effects can be maintained over time during repeated exposure.We have previously demonstrated that the acute protective effect of nitroglycerin (GTN) is attenuated during repeated daily administration. Pentaerythrityl tetranitrate (PETN) is an organic nitrate with different hemodynamic and biochemical properties. The purpose of the current experiment was to study the preconditioning-like effects of PETN and GTN during repeated daily exposure. METHODS AND RESULTS: In a randomized, investigator-blind parallel trial, 30 healthy (age 25-32) volunteers were randomized to receive (1) transdermal GTN (0.6 mg/h) administered for 2 h a day for 6 days; (2) oral PETN (80 mg) once a day for 6 days; or (3) no therapy. One week later, endothelium-dependent flow-mediated dilation was assessed before and after exposure to ischemia and reperfusion (IR). IR caused a significant blunting of the endothelium-dependent relaxation in the control group (FMD before IR: 5.8 ± 2.1%; after IR 1.0 ± 2.1%; P < 0.01). Daily, 2-h exposure to GTN partially prevented IR-induced endothelial dysfunction (FMD before IR: 7.7 ± 2.4%; after IR 4.3 ± 3.0%; P < 0.01 compared to before IR). In contrast, daily PETN administration afforded greater protection from IR-induced endothelial injury (FMD before IR: 7.9 ± 1.7%; after IR 6.4 ± 5.3%, P = ns; P < 0.05 ANOVA across groups). In vitro, incubation of human endothelial cells with GTN (but not PETN) was associated with inhibition (P < 0.01) of aldehyde dehydrogenase, an enzyme that is important for both nitrate biotransformation and ischemic preconditioning. DISCUSSION: We previously showed that upon repeated administration, the preconditioning-like effects of GTN are attenuated. The present data demonstrate a gradient in the extent of protection afforded by the two nitrates, suggesting that PETN-induced preconditioning is maintained after prolonged administration in a human in vivo model of endothelial dysfunction induced by ischemia. Using isolated human endothelial cells, we propose a mechanistic explanation for this observation based on differential effects of GTN versus PETN on the activity of mitochondrial aldehyde dehydrogenase.
RCT Entities:
INTRODUCTION:Ischemic and pharmacologic preconditioning have great clinical potential, but it remains unclear whether their effects can be maintained over time during repeated exposure.We have previously demonstrated that the acute protective effect of nitroglycerin (GTN) is attenuated during repeated daily administration. Pentaerythrityl tetranitrate (PETN) is an organic nitrate with different hemodynamic and biochemical properties. The purpose of the current experiment was to study the preconditioning-like effects of PETN and GTN during repeated daily exposure. METHODS AND RESULTS: In a randomized, investigator-blind parallel trial, 30 healthy (age 25-32) volunteers were randomized to receive (1) transdermal GTN (0.6 mg/h) administered for 2 h a day for 6 days; (2) oral PETN (80 mg) once a day for 6 days; or (3) no therapy. One week later, endothelium-dependent flow-mediated dilation was assessed before and after exposure to ischemia and reperfusion (IR). IR caused a significant blunting of the endothelium-dependent relaxation in the control group (FMD before IR: 5.8 ± 2.1%; after IR 1.0 ± 2.1%; P < 0.01). Daily, 2-h exposure to GTN partially prevented IR-induced endothelial dysfunction (FMD before IR: 7.7 ± 2.4%; after IR 4.3 ± 3.0%; P < 0.01 compared to before IR). In contrast, daily PETN administration afforded greater protection from IR-induced endothelial injury (FMD before IR: 7.9 ± 1.7%; after IR 6.4 ± 5.3%, P = ns; P < 0.05 ANOVA across groups). In vitro, incubation of human endothelial cells with GTN (but not PETN) was associated with inhibition (P < 0.01) of aldehyde dehydrogenase, an enzyme that is important for both nitrate biotransformation and ischemic preconditioning. DISCUSSION: We previously showed that upon repeated administration, the preconditioning-like effects of GTN are attenuated. The present data demonstrate a gradient in the extent of protection afforded by the two nitrates, suggesting that PETN-induced preconditioning is maintained after prolonged administration in a human in vivo model of endothelial dysfunction induced by ischemia. Using isolated human endothelial cells, we propose a mechanistic explanation for this observation based on differential effects of GTN versus PETN on the activity of mitochondrial aldehyde dehydrogenase.
Authors: P Wenzel; U Hink; M Oelze; A Seeling; T Isse; K Bruns; L Steinhoff; M Brandt; A L Kleschyov; E Schulz; K Lange; H Weiner; J Lehmann; K J Lackner; T Kawamoto; T Münzel; A Daiber Journal: Br J Pharmacol Date: 2007-01-15 Impact factor: 8.739
Authors: Christophe Depre; Ji Yeon Park; You-Tang Shen; Xin Zhao; Hongyu Qiu; Lin Yan; Bin Tian; Stephen F Vatner; Dorothy E Vatner Journal: Am J Physiol Heart Circ Physiol Date: 2010-06-25 Impact factor: 4.733
Authors: Zhiqiang Chen; Matthew W Foster; Jian Zhang; Lan Mao; Howard A Rockman; Toshihiro Kawamoto; Kyoko Kitagawa; Keiichi I Nakayama; Douglas T Hess; Jonathan S Stamler Journal: Proc Natl Acad Sci U S A Date: 2005-08-15 Impact factor: 11.205
Authors: Katalin Szöcs; Bernard Lassègue; Philip Wenzel; Maria Wendt; Andreas Daiber; Matthias Oelze; Thomas Meinertz; Thomas Münzel; Stephan Baldus Journal: J Mol Cell Cardiol Date: 2007-03-30 Impact factor: 5.000
Authors: You-Tang Shen; Christophe Depre; Lin Yan; Ji Yeon Park; Bin Tian; Komal Jain; Li Chen; Yan Zhang; Raymond K Kudej; Xin Zhao; Junichi Sadoshima; Dorothy E Vatner; Stephen F Vatner Journal: Circulation Date: 2008-10-20 Impact factor: 29.690
Authors: Olga Trojnarska; Ludwina Szczepaniak-Chicheł; Katarzyna Mizia-Stec; Marcin Gabriel; Agnieszka Bartczak; Stefan Grajek; Zbigniew Gąsior; Lucyna Kramer; Andrzej Tykarski Journal: Clin Res Cardiol Date: 2010-12-16 Impact factor: 5.460
Authors: Monica Lisi; Saverio Dragoni; Maria Cristina Leone; Thomas Münzel; John D Parker; Tommaso Gori Journal: Clin Res Cardiol Date: 2013-02-19 Impact factor: 5.460